Shengxiang Biotech announced that the company's product parainfluenza virus, human rhinovirus, adenovirus, and mycoplasma pneumoniae nucleic acid detection kit recently received a “Medical Device Registration Certificate” issued by the State Drug Administration. It is a domestic class III in vitro diagnostic reagent. The registration certificate is valid until October 8, 2031. This product is the company's second freeze-dried quadruple detection product. It can complement and cover 8 common respiratory pathogens with the first freeze-dried quadruple detection product, improving the company's respiratory infectious pathogen detection product matrix. The future performance of this product is affected by factors such as market expansion, and there is uncertainty about sales and profit contributions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.